Roles
- Associate Professor of Neuro-Oncology
- Chief, Neuro-Oncology Division
- Clinical Service Leader for Neuro-Oncology Service Line - Sylvester Comprehensive Cancer Center
- Chair, Neuro-Oncology Site Disease Group
- Neuro-Oncology Fellowship Program Director
- Oncology Clinical Service Leader for Neuro-Oncology
-
Biography
Dr. De la Fuente is the Chief of the Neuro-Oncology Division and Director of the Neuro-Oncology Fellowship Program, Department of Neurology, University of Miami and Neuro-Oncology Clinical Service Leader for the Oncology Service Line at Sylvester Comprehensive Cancer Center. Dr. De la Fuente is a graduate of the Neuro-Oncology Fellowship program at Memorial Sloan Kettering Cancer Center in New York, where she served as Consultant in the Department of Neurology after finishing her fellowship. Dr. De la Fuente is an active member of the Society for Neuro-Oncology (SNO) where she serves as one of the co-chairs of the Women and Diversity Committee. Dr. De la Fuente has been appointed by the President of the Florida Senate as a Member of the Scientific Advisory Council of the Florida Center for Brain Tumor Research. -
Education & Training
Education
Post Graduate Training
Licensures and Certifications
-
Honors & Awards
-
Teaching Interests
Dr. De la Fuente is the director of the Neuro-oncology fellowship program. -
Research Interests
Dr. De la Fuente's research focuses on clinical and translational research in primary human brain tumors with a goal to develop innovative, more effective treatments as well as develop radiographic biomarkers to better assess the efficacy of those treatments. This effort has been conducted along two tracks 1) Optimizing therapy for patients with low- and high-grade glioma using a combined approach of targeted therapies and or immunotherapy, and 2) developing molecular imaging through collaborations with basic research scientists. Dr. De la Fuente has a strong interest in gliomas and metabolic pathway alterations, particularly isocitrate dehydrogenase (IDH) mutations. Her work has been specifically focused on IDH inhibitors for the treatment of IDH mutant gliomas as well as the identification and clinical application novel radiographic biomarkers for IDH mutant gliomas. Dr. De la Fuente is currently leading and collaborating in multiple active research projects with colleagues from Neurosurgery, Radiology, Medicine, Pediatrics, Medical Physics, and Radiation Oncology. Dr. De la Fuente is a Memorial Sloan Kettering trained neuro-oncologist serving as principal investigator for several clinical trials, including IISs, as well as collaborations within NIH-funded cooperative groups and industry.
Dr. De la Fuente is deeply interested and invested in achieving diversity, equity, and inclusion (DEI) in the academic medical environment. As part of this commitment, she currently serves as one of the co-chairs of the Women and Diversity Committee of the Society for Neuro-Oncology (SNO) and as the Equity Focused Clinical Investigator (EfCI) for University of Miami to North American Star Consortium (NASC). -
Publications
Disclaimer: Information presented in this section has been consolidated using AI and machine learning technologies. While every effort has been made to ensure accuracy, errors may occur. If you identify any inaccuracies, use this link to inform our data team. Your feedback is appreciated and helps us improve the quality of our content.Professional Activities
Articles & News
How Team Science at Sylvester is Changing Brain Cancer Care
Q and A with Brain Cancer Expert Macarena de la Fuente
A Celebration of Innovation and Education
Disclaimer:
Information presented in this section has been consolidated using AI and machine learning technologies. While every effort has been made to ensure accuracy, errors may occur. If you identify any inaccuracies, use this link to inform our data team. Your feedback is appreciated and helps us improve the quality of our content.
Clinical Trials
Viewing 0 of 30 clinical trials.
-
This study is being done to answer the following question: Can we decrease the chance of your brain cancer growing or returning by adding a second drug to the usual drug after radiation therapy? We are doing this study because we want to find out if this approach is better or worse than the usual approach for your advanced brain cancer. The usual approach is defined as care most people get for advanced brain cancer.
- Principal Investigator: Macarena De La Fuente
- Study Phase: Phase III
- Enrollment Status: Open
-
In this study, an investigational medication called lixumistat (IM156) is being tested for the treatment of glioblastoma. Lixumistat works by interrupting a biological process that tumor cells use to resist treatment with chemotherapy. Participants will receive lixumistat treatment prior to receiving standard-of-care neurosurgery to remove their brain tumor(s), radiotherapy, and temozolomide chemotherapy. Standard-of-care treatment is medical care you would receive regardless of taking part in this study.
- Principal Investigator: Macarena De La Fuente
- Study Phase: N/A
- Enrollment Status: Open
-
The purpose of this study is to test the safety of a drug called triapine when combined with radiation therapy. This study tests different doses of the drug to see which dose is safer for people.
- Principal Investigator: Macarena De La Fuente
- Study Phase: Phase I
- Enrollment Status: Open
-
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study of AG-881 in Subjects With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation
- Principal Investigator: Macarena De La Fuente
- Study Phase: Phase 3
- Enrollment Status: Not Accepting
-
This abbreviated protocol has been created to address the medical needs of one patient with confirmed diagnosis of histiocytosis with BRAF V600E mutation with CNS involvement.
- Principal Investigator: Macarena De La Fuente
- Study Phase: N/A
- Enrollment Status: Closed
-
Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas With SMO/ AKT/ NF2/CDK Pathway Mutations
- Principal Investigator: Macarena De La Fuente
- Study Phase: Phase 2
- Enrollment Status: Open
-
A Phase 1/2a Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of FORE8394 in Patients With Advanced Unresectable Solid Tumors
- Principal Investigator: Macarena De La Fuente
- Study Phase: Phase 1/Phase 2
- Enrollment Status: Closed
-
GBM AGILE: Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent GBM
- Principal Investigator: Macarena De La Fuente
- Study Phase: Phase 2/Phase 3
- Enrollment Status: Open
-
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Enzastaurin Added to Temozolomide During and Following Radiation Therapy in Newly Diagnosed Glioblastoma Patients Who Possess the Novel Genomic Biomarker DGM1
- Principal Investigator: Macarena De La Fuente
- Study Phase: Phase 3
- Enrollment Status: Closed
-
A Phase 2 Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 Mutant Advanced Solid Tumors
- Principal Investigator: Macarena De La Fuente
- Study Phase: Phase 2
- Enrollment Status: Not Accepting
-
A Phase 1/2 Study of PBI-200 in Subjects With NTRK-Fusion-Positive Advanced or Metastatic Solid Tumors
- Principal Investigator: Macarena De La Fuente
- Study Phase: Phase 1/Phase 2
- Enrollment Status: Closed
-
A Proof-of-Concept, Pilot Study of Pembrolizumab (MK-3475) in Patients With Recurrent Malignant Glioma With a Hypermutator Phenotype
- Principal Investigator: Macarena De La Fuente
- Study Phase: N/A
- Enrollment Status: Not Accepting
-
A Phase 1, Dose-Escalation and Expansion Trial of PT2977, a HIF-2α Inhibitor, in Patients With Advanced Solid Tumors
- Principal Investigator: Macarena De La Fuente
- Study Phase: Phase 1
- Enrollment Status: Closed
-
Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas
- Principal Investigator: Macarena De La Fuente
- Study Phase: Phase 2
- Enrollment Status: Not Accepting
-
Pilot Study for Non-invasive Glioma Characterization Through Molecular Imaging
- Principal Investigator: Macarena De La Fuente
- Study Phase: N/A
- Enrollment Status: Open
-
The purpose of this expanded access request is to continue to provide experimental treatment (ABM-1310) of Recurrent, BRAF V600E mutant, WHO Grade 2 Pleomorphic Xanthoastrocytoma to a single patient.
- Principal Investigator: Macarena De La Fuente
- Study Phase: N/A
- Enrollment Status: Closed
-
An Open-Label, Multi-Center Trial of INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With REGN2810 in Subjects With Newly-Diagnosed Glioblastoma (GBM)
- Principal Investigator: Macarena De La Fuente
- Study Phase: Phase 1/Phase 2
- Enrollment Status: Closed
-
To evaluate the efficacy of maintenance safusidenib versus placebo in IDH1-mutant Grade 3 astrocytoma with high-risk features and Grade 4 astrocytoma following standard-of-care radiation or chemoradiation and adjuvant temozolomide. To compare overall survival (OS) between safusidenib and placebo. To evaluate the efficacy of safusidenib compared with placebo based on PFS by Investigator assessment.
- Principal Investigator: Macarena De La Fuente
- Study Phase: Phase II
- Enrollment Status: Open
-
A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-881 in Patients With Advanced Solid Tumors, Including Gliomas, With an IDH1 and/or IDH2 Mutation
- Principal Investigator: Macarena De La Fuente
- Study Phase: Phase 1
- Enrollment Status: Closed
-
A Randomized Phase 3 Single Blind Study of Temozolomide Plus Radiation Therapy Combined With Nivolumab or Placebo in Newly Diagnosed Adult Subjects With MGMT-Methylated (Tumor O6-methylguanine DNA Methyltransferase) Glioblastoma
- Principal Investigator: Macarena De La Fuente
- Study Phase: Phase 3
- Enrollment Status: Closed
-
A Randomized Phase 3 Open Label Study of Nivolumab vs Temozolomide Each in Combination With Radiation Therapy in Newly Diagnosed Adult Subjects With Unmethylated MGMT (Tumor O-6-methylguanine DNA Methyltransferase) Glioblastoma (CheckMate 498: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 498)
- Principal Investigator: Macarena De La Fuente
- Study Phase: Phase 3
- Enrollment Status: Closed
-
The purpose of this study to find out whether the drugs ABBV-637 and ABBV-155 are safe treatments that cause few or mild side effects when given alone or in combination with ERAS-801 in people with recurrent GBM. The other purposes of this study include looking at whether the study drugs work against recurrent GBM and how the body absorbs, distributes, and gets rid of the study drugs.
- Principal Investigator: Macarena De La Fuente
- Study Phase: Phase I
- Enrollment Status: Open
-
The purpose of this study is to test the good and bad effects of the drug called erdafitinib. Erdafitinib could shrink your cancer, but it could also cause side effects, which are described in the risks section below. The study doctors hope to learn if the study drug will shrink the cancer by at least one quarter compared to its present size.
- Principal Investigator: Macarena De La Fuente
- Study Phase: Phase II
- Enrollment Status: Not Accepting
-
Fore Biotherapeutics is conducting a research study to see if a new medicine not yet available outside clinical trials, named FORE8394, will serve as a treatment for cancer in adults whose tumors have an alteration in the BRAF gene. Some alterations in the BRAF gene can cause the growth of cancer. BRAF alterations can also cause cancers to grow more quickly than they would otherwise. Based on research findings of the roles of the BRAF gene in tumor growth, scientists have developed targeted medicines called BRAF inhibitors.
- Principal Investigator: Macarena De La Fuente
- Study Phase: Phase II
- Enrollment Status: Open
-
The aim of this study is to find out if the vorasidenib and temozolomide (TMZ) combination is safe in patients with IDH1- or IDH2-mutant gliomas. This study will also test how effective this treatment is against tumors in patients with Grade 4 IDH-mutant astrocytoma.
- Principal Investigator: Macarena De La Fuente
- Study Phase: Phase I/II
- Enrollment Status: Not Accepting
-
To provide GaM for compassionate use in patients with relapsed/refractory histologic or molecular glioblastoma who have exhausted available treatments.To collect sufficient information about the patients treatment to provide a complete and accurate case report to health authorities, including:● Assessment of GaM safety and tolerability● Assessment of patients response and duration of response using real-world data analysis ofimaging and biomarkers
- Principal Investigator: Macarena De La Fuente
- Study Phase: N/A
- Enrollment Status: Open
-
This treatment plan describes how to administer olutasidenib (FT-2102) to a patient who was previously enrolled in Clinical Study 2102-ONC-102 with an Advanced Solid Tumor or Glioma harboring an isocitrate dehydrogenase 1 (IDH1) mutation. Oral study drug.
- Principal Investigator: Macarena De La Fuente
- Study Phase: N/A
- Enrollment Status: Closed
-
The primary goal of this clinical research study is to determine the highest dose level a human can consume with therapeutic benefits from ABM-1310 when administered orally to adult patients with BRAF V600 mutated advanced solid tumors, which have progressed despite standard therapy or for whom no standard therapy exists.
- Principal Investigator: Macarena De La Fuente
- Study Phase: Phase I
- Enrollment Status: Closed
-
Vorasidenib is a drug that works by blocking mutant IDH1 and IDH2 proteins in the tumor. Pembrolizumab is a drug that works by helping your immune system to fight cancer. Pembrolizumab is being tested in this study with the goal of seeing how safe it is in patients when given with vorasidenib, and to see how safe and effective it is in patients when given with vorasidenib prior to surgical removal of their tumors, as well as after the surgery.
- Principal Investigator: Macarena De La Fuente
- Study Phase: Phase I
- Enrollment Status: Not Accepting
-
To determine the maximum tolerated dose of temozolomide followed by selinexor in recurrent glioblastoma patients as determined by dose-limiting toxicities (DLTs) and the total toxicity profile. (Phase I) II. To evaluate the efficacy of sequentially administering temozolomide and selinexor in recurrent glioblastoma as determined by progression-free survival (PFS). (Phase 2)
- Principal Investigator: Macarena De La Fuente
- Study Phase: Phase I/II
- Enrollment Status: Open